Shots:

• The US patent (17/877,699) covers the composition, specific physical characteristics, excipients, 5-HTP, and carbidopa doses, in vitro dissolution profiles, and human in vivo PK profiles of EVX-101
• In the P-I study, it demonstrated the ability to provide sustained and adequate 5-HTP exposure while ensuring safety and tolerability
• EVX-101 is a novel, proprietary gastro-retentive, sustained-release tablet formulation of 5-HTP, bilayers (swelling layer, and modified release layer), the natural precursor to serotonin, and low-dose carbidopa being developed for adjunctive therapy in major depressive disorder patients responding inadequately to a first-line serotonin reuptake inhibitor

Ref: Businesswire | Image: Evecxia Therapeutics